Gene Delivery of P53 in a Tumor-bearing Mouse Model

P53 在荷瘤小鼠模型中的基因传递

• 批准号: 7026946
• 负责人: ARCHIBALD JAMES MIXSON
• 金额: $ 26.75万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-05 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7026946
• 关键词: MCF7 cell; angiogenesis inhibitors; athymic mouse; biomaterial evaluation; biotechnology; clinical research; confocal scanning microscopy; disease /disorder model; fluorimetry; gene delivery system; gene expression; gene therapy; genetic transcription; human tissue; immunocytochemistry; in situ hybridization; laboratory mouse; liposomes; lung neoplasms; metastasis; neoplasm /cancer therapy; p53 gene /protein; polymers; skeletal neoplasm; terminal nick end labeling; transfection

DESCRIPTION (provided by applicant): Systemic gene delivery of p53 with cationic liposomes has been shown to reduce tumor growth in pre-clinical models. Although gene therapy with p53 may include several antiturnor mechanisms, antiangiogenesis is one important mechanism by which p53 inhibits tumor growth. Similar to other genes encoding antiangiogenic proteins, p53 gene therapy delivered by cationic liposomes is hampered by inadequate transfection in vivo. Recently our laboratory has developed linear and branched HK (histidine-lysine) polymers that in combination with liposomes significantly increased transfection in the presence or absence of serum. To test the overall hypothesis that further understanding of HK enhancement of transfection will facilitate the development of HK carriers for in vivo antiangiogenic gene therapy, the following specific aims are planned. Aim 1 will compare liposomes to HK/liposomes as gene delivery carriers of p53 for their ability to inhibit tumor growth. Since the tumor vasculature is readily accessible to systemic therapy, targeting tumor endothelial cells increases the likelihood that gene therapy will be successful. Two promising HK/liposome/p53 plasmid complexes will be compared to a liposome/p53 plasmid complex for their ability to reduce tumor angiogenesis and growth in vivo. To enhance specificity and antitumor efficacy of p53 in vivo, these HK-containing carriers will be modified with a vascular specific cyclic peptide (-NGR-) and a hydrophilic shield (PEG). Because the tumor endothelium is a primary target of complexes in vivo, we will test our hypothesis that the addition of HK polymers to liposome/p53 plasmid complexes will significantly improve gene therapy resulting in greater tumor inhibition. Since instability of the complexes in serum limits in vivo efficacy, Aim 2 is designed to clarify the mechanism by which the HK polymer enhances stability of liposome:DNA complexes in the presence of serum. In contrast to poly-L-lysine, the presence of HK maintains high level of gene expression and markedly enhances resistance of the liposome:DNA complex to serum, even with prolonged incubations. Whether hydrogen bonding or hydrophobic properties of histidine stabilize the HK:liposome:DNA complexes in the presence of serum will be tested. In Aim 3 the role of binding of HK to DNA in transfection will be examined to test the hypothesis that the interplay between different affinities of these polymers with DNA and the cell's endosomal pH accounts for variations in transfection efficiency. The ability to alter the histidine and lysine ratio and the complexity of the HK polymer is likely to change endosomal pH, which may affect binding and transfection efficiency. Understanding these properties that govern DNA release from the HK/liposome carrier within acidic endosomes will enable the development of improved carriers. Aim 4 is designed to use information gathered in the above aims to compare the derivatives of HK for their abilities to inhibit tumor growth. Based on the mechanistic studies determined in the previous aims, improved designs of the HK carrier will be developed. In combination with modified liposomes, several HK polymers will be compared with the optimal carrier in Aim 1 for their ability to augment the antitumor activity of p53 in vivo. The modified HK-containing carriers of p53 will be investigated for their antitumor activity of lung metastases and orthotopically implanted tumors.

描述（由申请人提供）：在临床前模型中，已显示用阳离子脂质体进行p53的全身基因递送可减少肿瘤生长。尽管p53基因治疗可能包括几种抗肿瘤机制，但抗血管生成是p53抑制肿瘤生长的一个重要机制。与其他编码抗血管生成蛋白的基因类似，通过阳离子脂质体递送的p53基因治疗受到体内转染不足的阻碍。最近，我们的实验室已经开发了线性和分支HK（组氨酸-赖氨酸）聚合物，在与脂质体的组合显着增加转染在血清的存在或不存在。为了检验进一步理解HK增强转染将促进用于体内抗血管生成基因治疗的HK载体的开发的总体假设，计划了以下具体目标。目的1将比较脂质体和HK/脂质体作为p53基因递送载体的抑制肿瘤生长的能力。由于肿瘤血管系统易于接受全身治疗，因此靶向肿瘤内皮细胞增加了基因治疗成功的可能性。两种有前途的HK/脂质体/p53质粒复合物将与脂质体/p53质粒复合物比较它们在体内减少肿瘤血管生成和生长的能力。为了增强p53在体内的特异性和抗肿瘤功效，这些含HK的载体将用血管特异性环肽（-NGR-）和亲水性屏蔽物（PEG）修饰。由于肿瘤内皮是体内复合物的主要靶点，我们将检验我们的假设，即在脂质体/p53质粒复合物中加入HK聚合物将显著改善基因治疗，从而产生更大的肿瘤抑制。由于复合物在血清中的不稳定性限制了体内功效，目的2旨在阐明HK聚合物在血清存在下增强脂质体：DNA复合物稳定性的机制。与聚-L-赖氨酸相反，HK的存在保持高水平的基因表达，并显著增强脂质体：DNA复合物对血清的抗性，即使长时间孵育也是如此。将检测组氨酸的氢键或疏水性质是否在血清存在下稳定HK：脂质体：DNA复合物。在目标3中，将检查HK与DNA在转染中的结合的作用，以检验这些聚合物与DNA的不同亲和力和细胞的内体pH之间的相互作用导致转染效率变化的假设。改变组氨酸和赖氨酸比率以及HK聚合物的复杂性的能力可能改变内体pH，这可能影响结合和转染效率。了解这些性质，支配DNA释放从HK/脂质体载体内的酸性内体将使改进的载体的发展。目的4旨在使用上述目的中收集的信息来比较HK衍生物抑制肿瘤生长的能力。基于在以前的目标中确定的机械研究，将开发HK载体的改进设计。与修饰的脂质体组合，将比较几种HK聚合物与目标1中的最佳载体，以确定它们增强p53体内抗肿瘤活性的能力。将研究经修饰的含HK的p53载体对肺转移瘤和原位植入肿瘤的抗肿瘤活性。